Literature DB >> 23907568

Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma.

Ping-Li Sun1, Yan Jin, Hyojin Kim, An Na Seo, Sanghoon Jheon, Choon-Taek Lee, Jin-Haeng Chung.   

Abstract

Survivin is a member of the inhibitors of apoptosis and frequently overexpressed in various cancer cells. Overexpression of survivin in lung cancer cells attenuates antitumor effect of tyrosine kinase inhibitors. However, data from the previous studies on the clinicopathologic implication of survivin in non-small-cell lung carcinoma (NSCLC) are inconsistent. We investigated the expression of survivin in 373 cases of surgically resected NSCLC. Correlations between the expression of survivin and clinicopathologic, molecular features and prognostic significance were analyzed. In adenocarcinoma, the increased expression of survivin was associated with the presence of vascular invasion, lymph node metastasis, and tumor recurrences, but we didn't find any correlation with survivin expression and clinicopathological parameters in squamous cell carcinoma. Patients with high survivin expression had significantly shorter disease-free survival (DFS; 42.2 vs. 58.8 months; p = 0.001) and shorter overall survival (OS; 60.8 vs. 71.5 months; p = 0.009) than those with low survivin expression group in adenocarcinoma. In squamous cell carcinoma, the expression of survivin was not associated with prognosis of the patients (DFS; 48.9 vs. 48.7 months; p = 0.837, OS; 61.0 vs. 62.4 months; p = 0.771). Multivariate analysis confirmed that survivin was an independent poor prognostic factor in adenocarcinoma (DFS: hazard ratio (HR), 1.687; 95 % confidence interval (CI), 1.123-2.532; p = 0.012; OS: HR, 1.965; 95 % CI, 1.108-3.486; p = 0.021). There was no statistically significant difference in the expression of survivin among different molecular subgroups (p > 0.05). Our results suggest that survivin is an independent negative prognostic factor in adenocarcinoma, but not in squamous cell carcinoma. The different prognostic roles played by survivin in adenocarcinoma and squamous cell carcinoma highlights the biological differences between these two histologic types.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23907568     DOI: 10.1007/s00428-013-1462-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  29 in total

Review 1.  Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.

Authors:  Pablo Perez-Moreno; Elisabeth Brambilla; Roman Thomas; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2012-03-08       Impact factor: 12.531

Review 2.  Lung cancer.

Authors:  Roy S Herbst; John V Heymach; Scott M Lippman
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

Review 3.  Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.

Authors:  Sunil Singhal; Anil Vachani; Danielle Antin-Ozerkis; Larry R Kaiser; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

4.  High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.

Authors:  Ping-Li Sun; Hyesil Seol; Hyun Ju Lee; Seol Bong Yoo; Hyojin Kim; Xianhua Xu; Sanghoon Jheon; Choon-Taek Lee; Jong-Suk Lee; Jin-Haeng Chung
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

5.  Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.

Authors:  Hyojin Kim; Seol-Bong Yoo; Ji-Young Choe; Jin Ho Paik; Xianhua Xu; Hiroaki Nitta; Wenjun Zhang; Thomas M Grogan; Choon-Taek Lee; Sanghoon Jheon; Jin-Haeng Chung
Journal:  J Thorac Oncol       Date:  2011-08       Impact factor: 15.609

Review 6.  Treat cancers by targeting survivin: just a dream or future reality?

Authors:  Mohane Selvaraj Coumar; Fang-Ying Tsai; Jagat Rakesh Kanwar; Sailu Sarvagalla; Chun Hei Antonio Cheung
Journal:  Cancer Treat Rev       Date:  2013-02-28       Impact factor: 12.111

7.  Survivin expression impacts prognostically on NSCLC but not SCLC.

Authors:  Antonio Rosato; Chiara Menin; Daniela Boldrin; Silvia Dalla Santa; Laura Bonaldi; Maria Chiara Scaini; Paola Del Bianco; Davide Zardo; Matteo Fassan; Rocco Cappellesso; Ambrogio Fassina
Journal:  Lung Cancer       Date:  2012-12-04       Impact factor: 5.705

8.  Survivin expression in atypical adenomatous hyperplasia of the lung.

Authors:  Kuniaki Nakanishi; Toshiaki Kawai; Fumiyuki Kumaki; Sadayuki Hiroi; Makio Mukai; Eiji Ikeda
Journal:  Am J Clin Pathol       Date:  2003-11       Impact factor: 2.493

9.  Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

Authors:  Anthony W Tolcher; Alain Mita; Lionel D Lewis; Christopher R Garrett; Elizabeth Till; Adil I Daud; Amita Patnaik; Kyri Papadopoulos; Chris Takimoto; Pamela Bartels; Anne Keating; Scott Antonia
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 50.717

10.  Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients.

Authors:  A R Hinnis; J C A Luckett; R A Walker
Journal:  Br J Cancer       Date:  2007-02-06       Impact factor: 7.640

View more
  13 in total

1.  Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.

Authors:  Yao-Kuang Wu; Chun-Yao Huang; Mei-Chen Yang; Chou-Chin Lan; Chih-Hsin Lee; Err-Cheng Chan; Kuei-Tien Chen
Journal:  Med Oncol       Date:  2014-06-25       Impact factor: 3.064

2.  Neutrophil-Lymphocyte Ratio as a Prognostic Marker for Lung Adenocarcinoma After Complete Resection.

Authors:  Yusuke Takahashi; Masafumi Kawamura; Tai Hato; Masahiko Harada; Noriyuki Matsutani; Hirotoshi Horio
Journal:  World J Surg       Date:  2016-02       Impact factor: 3.352

3.  SIRT1 expression is associated with poor prognosis of lung adenocarcinoma.

Authors:  Chong Li; Lingling Wang; Liang Zheng; Xianghong Zhan; Bin Xu; Jingting Jiang; Changping Wu
Journal:  Onco Targets Ther       Date:  2015-04-30       Impact factor: 4.147

4.  From Proteomic Analysis to Potential Therapeutic Targets: Functional Profile of Two Lung Cancer Cell Lines, A549 and SW900, Widely Studied in Pre-Clinical Research.

Authors:  Luís Korrodi-Gregório; Vanessa Soto-Cerrato; Rui Vitorino; Margarida Fardilha; Ricardo Pérez-Tomás
Journal:  PLoS One       Date:  2016-11-04       Impact factor: 3.240

5.  Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.

Authors:  Toshiyuki Sumi; Sachie Hirai; Miki Yamaguchi; Yusuke Tanaka; Makoto Tada; Gen Yamada; Tadashi Hasegawa; Yohei Miyagi; Toshiro Niki; Atsushi Watanabe; Hiroki Takahashi; Yuji Sakuma
Journal:  Int J Oncol       Date:  2018-04-11       Impact factor: 5.650

6.  Comprehensive analysis of spread through air spaces in lung adenocarcinoma and squamous cell carcinoma using the 8th edition AJCC/UICC staging system.

Authors:  Meng Jia; Shili Yu; Jiaqi Yu; Yuemin Li; Hongwen Gao; Ping-Li Sun
Journal:  BMC Cancer       Date:  2020-07-29       Impact factor: 4.430

7.  Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.

Authors:  A N Seo; J M Yang; H Kim; S Jheon; K Kim; C T Lee; Y Jin; S Yun; J-H Chung; J H Paik
Journal:  Br J Cancer       Date:  2014-05-08       Impact factor: 7.640

8.  Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis.

Authors:  Liang Duan; Xuefei Hu; Yuxing Jin; Ruijun Liu; Qingjun You
Journal:  BMC Cancer       Date:  2016-04-18       Impact factor: 4.430

9.  [Occurrence and survival condition of lung cancer with different histologies among residents in Pudong new area].

Authors:  Hanyi Chen; Chen Yang; Bei Yan; Lianghong Sun; Zheng Wu; Xiaopan Li; Meiyu Zhang; Xiaoli Li; Liming Yang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-03

10.  Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Authors:  Rita Puskas; Andras Bikov; Peter Horvath; Zsofia Lazar; Laszlo Kunos; Reka Nagy; Gabriella Pinter; Gabriella Galffy
Journal:  Pathol Oncol Res       Date:  2021-04-30       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.